Literature DB >> 12939656

Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation.

Florian Kronenberg1, Karl Lhotta, Paul König, Raimund Margreiter, Hans Dieplinger, Gerd Utermann.   

Abstract

The atherogenic lipoprotein(a) (Lp(a)) is significantly increased in patients with kidney disease. Some studies in hemodialysis patients described this increase to be dependent on the genetic apolipoprotein(a) (apo(a)) isoforms. Only patients who express high molecular weight (HMW) apo(a) isoforms but not those with low molecular weight (LMW) isoforms show a relative increase of Lp(a) when compared to healthy controls matched for apo(a) isoforms. However, this was not confirmed by all studies. We therefore prospectively investigated the changes of Lp(a) deriving from each apo(a) isoform in heterozygotes following kidney transplantation. Lp(a) concentrations were measured by ELISA. To calculate the isoform-specific concentrations and the changes of Lp(a) deriving from each isoform, we densitometrically scanned the apo(a) bands from immunoblots before and after transplantation in 20 patients expressing two apo(a) isoforms. Of these, 10 patients expressed both an LMW and an HMW apo(a) isoform. The other 10 patients expressed only HMW isoforms. Densitometric scanning of apo(a) bands and calculation of isoform-derived Lp(a) concentrations clearly demonstrated that the decrease of Lp(a) following kidney transplantation is caused by changes in the expression of HMW apo(a) isoforms. In some patients, we observed an almost complete disappearance of the HMW apo(a) isoform after transplantation. This study clearly demonstrates that the changes of Lp(a) plasma concentrations in kidney disease depend on the genetically determined size of apo(a). This provides evidence for an interaction of apo(a) genetic variability and kidney function on Lp(a) concentrations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939656     DOI: 10.1038/sj.ejhg.5201016

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  6 in total

Review 1.  PCSK9 in chronic kidney disease.

Authors:  P Pavlakou; E Liberopoulos; E Dounousi; M Elisaf
Journal:  Int Urol Nephrol       Date:  2017-01-13       Impact factor: 2.370

Review 2.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

3.  Circulating PCSK9 is lowered acutely following surgery.

Authors:  Irena Druce; Hussein Abujrad; Seham Chaker; Hilary Meggison; Andrew Hill; Angela Raymond; Janice Mayne; Teik Chye Ooi
Journal:  J Clin Lab Anal       Date:  2017-11-17       Impact factor: 2.352

4.  Lipoprotein(a) accelerates atherosclerosis in uremic mice.

Authors:  Tanja X Pedersen; Sally P McCormick; Sotirios Tsimikas; Susanne Bro; Lars B Nielsen
Journal:  J Lipid Res       Date:  2010-06-28       Impact factor: 5.922

Review 5.  Non-genetic influences on lipoprotein(a) concentrations.

Authors:  Byambaa Enkhmaa; Lars Berglund
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

Review 6.  The role of lipoprotein (a) in chronic kidney disease.

Authors:  Jemma C Hopewell; Richard Haynes; Colin Baigent
Journal:  J Lipid Res       Date:  2018-01-29       Impact factor: 5.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.